Target Name: MIR203A
NCBI ID: G406986
Review Report on MIR203A Target / Biomarker Content of Review Report on MIR203A Target / Biomarker
MIR203A
Other Name(s): hsa-miR-203a-5p | hsa-miR-203a-3p | MiRNA203 | MIR203 | microRNA 203a | hsa-mir-203a | miRNA203 | MicroRNA 203a | miR-203 | mir-203a | MIRN203

Overview of MIR203A: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

MIR203A (hsa-miR-203a-5p) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. The molecule is derived from the microRNA (miRNA) family, which is a group of small non-coding RNAs that play a crucial role in post-transcriptional gene regulation. In this article, we will provide an overview of MIR203A, its potential drug target status, and its potential clinical applications.

Structure and Function

MIR203A is a 20-mer RNA molecule with a unique 5' end that contains a loop region and a 3' end that contains a stem-loop region. The molecule has a highly conserved core structure, with a conserved G-C ratio and a preference for A-U pairs. MIR203A has a predicted localization in the nucleus, and it is primarily expressed in the liver, heart, and brain.

MIR203A has been shown to play a role in various biological processes, including cell growth, apoptosis, and metabolism. MIR203A has been shown to regulate the expression of target genes by binding to specific miRNA target sites. The binding of MIR203A to a target gene can lead to the inhibition of the target gene's translation or degradation.

Drug Target Status

MIR203A has been identified as a potential drug target for various diseases, including cancer. Several studies have shown that inhibiting MIR203A can lead to the inhibition of target genes, which can lead to the inhibition of cell growth and the inhibition of the disease.

One of the studies that identified MIR203A as a potential drug target for cancer was published in the journal Nature Communications in 2013. In this study, the authors showed that MIR203A was highly expressed in various cancer tissues and that inhibiting the expression of MIR203A using RNA interference (RNAi) led to the inhibition of the growth of cancer cells.

Another study that identified MIR203A as a potential drug target for cancer was published in the journal Oncology Reports in 2016. In this study, the authors showed that MIR203A was expressed in various cancer tissues and that inhibiting the expression of MIR203A using small interfering RNA (siRNA) led to the inhibition of the growth of cancer cells.

Potential Clinical Applications

MIR203A has the potential to be a drug target or biomarker for various diseases, including cancer. The inhibition of MIR203A has been shown to lead to the inhibition of target genes, which can lead to the inhibition of cell growth and the inhibition of the disease.

One of the potential clinical applications of MIR203A is as a treatment for cancer. The inhibition of MIR203A has been shown to lead to the inhibition of cancer cell growth, which can lead to the inhibition of the progression of cancer.

Another potential clinical application of MIR203A is as a biomarker for cancer. The inhibition of MIR203A has been shown to lead to the inhibition of cancer cell growth, which can be used as a biomarker for cancer.

Conclusion

MIR203A is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. The molecule is derived from the microRNA

Protein Name: MicroRNA 203a

The "MIR203A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR203A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2